Výsledky vyhledávání - "A Fuentes-Alburo"

Akademický článek

Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US.

Autor: Regina Munter-Young, Adolfo Fuentes-Alburo, Nicholas DiGregorio, Kurt Neeser, Dmitry Gultyaev

Publikováno v: PLoS ONE, Vol 19, Iss 5, p e0302486 (2024)

Background and objectivesCorrect identification of estrogen receptor (ER) status in breast cancer (BC) is crucial to optimize treatment; however, standard of care, involving biopsy and immunohistochemistry (IHC), and other diagnostic tools such as 2-

Externí odkaz: https://doaj.org/article/ffe78734fd1a4b42a6f1d207a4fd13f3

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Final overall survival analysis of the phase 3 HERITAGE study demonstrates equivalence of trastuzumab-dkst to trastuzumab in HER2-positive metastatic breast cancer

Publikováno v: Breast Cancer Research and Treatment
Breast cancer research and treatment, vol 188, iss 2

Purpose The phase 3 HERITAGE trial demonstrated that the biosimilar trastuzumab-dkst is well tolerated with similar efficacy (measured by overall response rate [ORR] and progression-free survival [PFS]) compared with originator trastuzumab combined w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d96d7db24623d3a61483158ddd9eb8f3
https://doi.org/10.1007/s10549-021-06197-5

Zobrazit plný text záznamu

Intravenous and subcutaneous formulations of trastuzumab, and trastuzumab biosimilars: implications for clinical practice

Autor: Cornelius F. Waller, Adolfo Fuentes-Alburo, Julia Möbius

Publikováno v: British Journal of Cancer

Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic gastric cancer. Trastuzumab was originally approved as an intravenous (IV) formulation but has sinc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::add11b2de4a463cf6c4ca5b653ca8b44
https://doi.org/10.1038/s41416-020-01255-z

Zobrazit plný text záznamu

Abstract PS18-23: Population pharmacokinetics (Pop PK) of MYL-1401O (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2-positive metastatic breast cancer (mBC)

Autor: Joel Owen, Cornelius F. Waller, Hope S. Rugo, Abhijit Barve, Adolfo Fuentes-Alburo, Russell J. Rackley, Tazeen Idris, Subramanian Loganathan, Mark Liu

Publikováno v: Cancer Research. 81:PS18-23

Background: Mylan trastuzumab (MYL-1401O) is a biosimilar to trastuzumab (Herceptin®). A multicenter, double blind, randomized, phase III study (HERITAGE) compared the efficacy, safety, Pop PK and immunogenicity of MYL-1401O and trastuzumab in patie

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::35c60c714b9f37a60335c98444ee90fe
https://doi.org/10.1158/1538-7445.sabcs20-ps18-23

Zobrazit plný text záznamu

Conversion from pegfilgrastim with on-body injector to pegfilgrastim-jmdb: cost-efficiency analysis and budget-neutral expanded access to prophylaxis and treatment

Autor: Ali McBride, Karen MacDonald, Ivo Abraham, Adolfo Fuentes-Alburo

Publikováno v: Journal of Medical Economics. 24:598-606

Therapeutic guidelines recommend prophylaxis against chemotherapy-induced (febrile) neutropenia (CIN/FN). Pegfilgrastim (Neulasta), biosimilar pegfilgrastim-jmdb (Fulphila), and pegfilgrastim with on-body injector (OBI; Neulasta Onpro) are options fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::459953fa26e91c2a4563ffc7ca05248c
https://doi.org/10.1080/13696998.2021.1916863

Zobrazit plný text záznamu

Abstract OT2-01-01: Trial in Progress: Clinical Utility of Fluoroestradiol F18 PET/CT in Metastatic Breast Cancer Patients with ER-Positive and HER2-Negative Primary Lesions after Progression on First Line Hormonal Therapy

Autor: Stephanie van de Ven, Feng Luo, Nicholas DiGregorio, Adolfo Fuentes-Alburo, Francois Tranquart

Publikováno v: Cancer Research. 83:OT2-01

BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy are the recommended first-line standard-of-care (SOC) treatment for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc601d74218758451efde9f8f748922f
https://doi.org/10.1158/1538-7445.sabcs22-ot2-01-01

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání